Pfizer and Ligand Pharmaceuticals have announced the FDA acceptance of bazedoxifene/conjugated estrogens (BZA/CE) new drug application (NDA) for review. The BZA/CE is an investigational therapy developed by Wyeth Pharmaceuticals to tackle ...
Tags: estrogens NDA, Pharmaceuticals, FDA, menopausal symptoms
European Medicines Agency (EMA) has accepted to review Pfizer's marketing authorization application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE). BZA/CE is designed for postmenopausal women with a uterus for the treatment of ...
Tags: bazedoxifene conjugated estrogens, BZA/CE, estrogen deficiency symptoms